SEC Form 4 · accession 0001127602-17-026940
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William P Sheridan
Officer — Senior VP - CMO
Period of report
Aug 31, 2017
Accepted (ET)
Sep 5, 2017 · 3:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emp. Stock Option (Right to Buy)F1 | $11.13 | Aug 31, 2017 | A | 33,900 | A | Aug 31, 2017 | Dec 22, 2024 | Common Stock | 33,900 | 33,900 | D |
Explanation of responses
- F1On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded in December 2014 to all employees, excluding the Chief Executive Officer, has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017.